- Home
- VOGX vs KAZR Comparison
VOGX vs KAZR Comparison
Compare VOGX & KAZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOGX | KAZR |
|---|---|---|
| Founded | 2021 | 2024 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.8M | 398.1M |
| IPO Year | 2026 | 2024 |
Fundamental Metrics
Financial Performance| Metric | VOGX | KAZR |
|---|---|---|
| Price | $19.50 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 70.9K | ★ 107.0K |
| Earning Date | 11-19-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.50 | $1.43 |
| 52 Week High | $38.41 | $3.20 |
Technical Indicators
Market Signals| Indicator | VOGX | KAZR |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 24.77 |
| Support Level | $14.61 | N/A |
| Resistance Level | $22.24 | $2.35 |
| Average True Range (ATR) | 2.60 | 0.22 |
| MACD | 0.71 | -0.05 |
| Stochastic Oscillator | 79.60 | 11.21 |
Price Performance
Historical ComparisonAbout VOGX Vogenx Inc Common Stock
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.